These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 19934278)
1. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278 [TBL] [Abstract][Full Text] [Related]
2. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036 [TBL] [Abstract][Full Text] [Related]
4. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029 [TBL] [Abstract][Full Text] [Related]
5. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648 [TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120 [TBL] [Abstract][Full Text] [Related]
7. EZH2 methyltransferase and H3K27 methylation in breast cancer. Yoo KH; Hennighausen L Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105 [TBL] [Abstract][Full Text] [Related]
8. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193 [TBL] [Abstract][Full Text] [Related]
9. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. Au SL; Wong CC; Lee JM; Wong CM; Ng IO PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380 [TBL] [Abstract][Full Text] [Related]
10. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008 [TBL] [Abstract][Full Text] [Related]
14. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826 [TBL] [Abstract][Full Text] [Related]
15. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619 [TBL] [Abstract][Full Text] [Related]
16. Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers. Chu Y; Wang Y; Zhang G; Chen H; Dowdy SC; Xiong Y; Liu F; Zhang R; Li J; Jiang SW Cell Mol Life Sci; 2014 Sep; 71(17):3393-408. PubMed ID: 24531693 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. Chen H; Tu SW; Hsieh JT J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459 [TBL] [Abstract][Full Text] [Related]
19. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. Mossman D; Kim KT; Scott RJ BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997 [TBL] [Abstract][Full Text] [Related]
20. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]